EGETIS THERAPEUTICS AB NPV revenue for the last year amounted to 57.60 M SEK, the most of which — 57.60 M SEK — came from its highest performing source at the moment, Emcitate, the year earlier bringing 21.90 M SEK. The greatest contribution to the revenue figure was made by Germany — last year it brought EGETIS THERAPEUTICS AB NPV 16.90 M SEK.